TBPH
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Theravance Biopharma reported that its Phase 3 CYPRESS study failed to meet the primary endpoint and said the board accelerated a strategic review while implementing cost reductionsMar 3, 2026
- Theravance Biopharma completes enrollment in pivotal Phase 3 CYPRESS study of Ampreloxetine in symptomatic neurogenic orthostatic hypotension due to multiple system atrophyAug 25, 2025
- Theravance Biopharma announces approval of YUPELRI® (revefenacin) by China's NMPAJun 26, 2025